Cannabis and Crohn's Disease
Cannabis relieves Crohn's symptoms but does not heal bowel inflammation—understand the evidence and limitations.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis can reduce pain, nausea, and loss of appetite in Crohn's patients—that's real. The catch: your gut can feel better while inflammation silently damages the intestines. Large trials found no improvement in blood markers or endoscopy scopes. It's a symptom tool, not a disease modifier. Use it as an add-on to prescribed therapy, not a replacement. Talk to your gastroenterologist first.
⚠️ This Is Not Medical Advice
Crohn's disease is a serious, progressive condition that can cause bowel damage, fistulas, abscesses, and require surgery if undertreated. Do not substitute cannabis for therapy prescribed by a gastroenterologist. Talk to your IBD care team before adding cannabis, especially if you take biologics, immunomodulators, or corticosteroids. The information below summarizes peer-reviewed research and clinical trial data; it is not personalized medical guidance.
Plain-Language Summary
Crohn's disease is a chronic inflammation of the gut lining. The intestines contain cannabinoid receptors (CB1 and CB2), and your body makes its own cannabinoid-like molecules that help regulate gut movement, pain signaling, and immune response [1][2]. That biology is why researchers have investigated cannabis for Crohn's.
When tested in humans, the pattern across multiple small trials is consistent: patients feel meaningfully better, but their gut does not look better on endoscopy or show improvement in blood inflammation markers [3][4][5]. So cannabis appears to work as a symptom-control tool, not as a disease-modifier or cure. Whether that benefit is worthwhile depends on your situation—some patients in remission with leftover symptoms (pain, poor appetite, sleep trouble) benefit significantly; patients with active, damaging inflammation still need standard therapy.
What Probably Works
Symptom relief and quality of life
In a placebo-controlled trial by Naftali and colleagues (2013), 21 patients with active Crohn's who had failed standard therapy smoked THC-rich cannabis or placebo cigarettes for 8 weeks [3]. The cannabis group had large improvements in the Crohn's Disease Activity Index (CDAI), pain scores, appetite, and sleep quality Weak / limited. A later randomized controlled trial by the same group tested oral CBD-rich cannabis oil (not THC-dominant) in 20 patients; it showed similar improvements in symptom burden and quality-of-life measures despite no change in C-reactive protein (CRP) or fecal calprotectin (inflammatory markers) [4] Weak / limited.
Reduced reliance on other medications
In the 2013 trial, 5 of 11 cannabis patients achieved clinical remission by CDAI score, and several reduced or stopped corticosteroid use [3] Weak / limited. Observational and survey studies of IBD patients across the US and Canada report a similar pattern of patients reducing opioid and steroid doses after starting cannabis [6] Weak / limited.
Appetite and body weight
THC stimulates appetite via effects on hypothalamic feeding circuits [7] Strong evidence. This is clinically relevant because malnutrition and weight loss are common complications of Crohn's disease.
What Might Work
Steroid-sparing effect
Suggested by trial data and patient surveys but never tested as a primary outcome in an adequately powered randomized trial [3][6] Weak / limited. This remains an open question.
CBD alone (without THC)
A small randomized controlled trial of purified CBD (10 mg twice daily) in Crohn's patients showed no benefit over placebo, but the dose was likely too low to produce a biological effect [8] Weak / limited. A separate trial using higher-dose CBD-rich whole-plant oil (20–30 mg CBD daily in two divided doses) did show symptom and quality-of-life benefits [4]. The honest read: CBD alone may contribute to symptom relief, but the THC component appears to do most of the symptomatic heavy lifting based on current data.
Post-operative outcomes and fistula healing
Biologically plausible from CB2-receptor work in animal models of intestinal injury [2], but human evidence is essentially absent No data.
What Doesn't Work or Has Weak Evidence
Mucosal healing
This is the most important finding to understand. In the Naftali trials, C-reactive protein, fecal calprotectin, and endoscopic inflammation scores did not improve with cannabis, even when patients reported dramatic symptom relief [3][4] Weak / limited. In modern IBD care, mucosal healing—not just symptom control—is the primary treatment target because ongoing silent inflammation damages the bowel lining, increases surgery risk, and can lead to complications like strictures and fistulas [10].
Cannabis as monotherapy for moderate-to-severe Crohn's
No evidence supports using cannabis as a sole treatment for active Crohn's disease, and given the absence of mucosal healing, it is not a reasonable substitute for biologics, immunomodulators, or aminosalicylates [3][4][5] No data.
Strain-specific claims
Claims that "indica is better for Crohn's" or that particular terpene profiles (e.g., myrcene, linalool) work better are folklore without controlled research No data.
Heavy cannabis use and surgical outcomes
A retrospective study found that heavy cannabis users with IBD had higher rates of surgery and post-operative complications; however, confounding by disease severity, disease duration, and adherence to standard therapy is likely and not adequately controlled for [9] Disputed.
What We Don't Know
- Whether cannabis changes long-term disease progression, bowel damage, or need for surgery. No long-term randomized trials exist.
- Optimal cannabinoid ratio, dose, and route. Existing trials used smoked flower or oral oils; inhaled/vaporized formulations have not been compared head-to-head in Crohn's patients.
- Whether cannabis interacts meaningfully with biologics (infliximab, adalimumab, ustekinumab, vedolizumab) or immunomodulators (azathioprine, methotrexate). Pharmacokinetic data is limited No data.
- Whether the pattern of symptomatic improvement without mucosal healing reflects a true analgesic and anti-nausea effect that masks ongoing inflammation—a real concern raised by IBD specialists in published commentaries [5][10].
- Pediatric use: essentially unstudied in randomized trials and not recommended outside research settings.
- Whether CBD's inhibition of cytochrome P450 enzymes has clinical significance in patients on complex IBD regimens [12].
Comparison with Standard Treatments
Standard Crohn's therapy is built around inducing and maintaining mucosal healing: corticosteroids (short-term disease induction), immunomodulators (azathioprine, methotrexate), biologics (anti-TNF agents such as infliximab, anti-integrins such as vedolizumab, anti-IL-12/23 agents such as ustekinumab), and small-molecule JAK inhibitors. These have been shown in large randomized controlled trials to heal the gut lining and reduce rates of surgery and hospitalization [10] Strong evidence.
Cannabis has not been shown to achieve any of those endpoints. Where it fits, based on current evidence, is as an add-on for symptom control—pain, nausea, poor appetite, sleep disturbance, and overall quality of life—in patients whose underlying disease is being managed (or actively being treated) with standard therapy [3][4][6]. Some IBD specialists view it as a reasonable harm-reduction alternative to opioids for chronic Crohn's-related pain given the comparatively lower risk of dependence and overdose Weak / limited.
For more context on IBD broadly, see Cannabis and Inflammatory Bowel Disease. For related considerations on chronic pain management, see Cannabis and Chronic Pain. For drug interactions, see Cannabis and Polypharmacy Risks.
Risks and Cautions
Symptom masking (Crohn's-specific)
The most important IBD-specific risk: feeling better while inflammation silently damages the bowel. This can delay recognition of a flare or allow disease progression undetected. Continue regular monitoring with your GI team (stool calprotectin, periodic endoscopy) regardless of subjective symptom improvement [5][10] Strong evidence.
Cannabis use disorder
Roughly 1 in 10 adult cannabis users develop dependence; risk is higher with daily use and high-THC products [11] Strong evidence.
Cognitive and psychiatric effects
THC can worsen anxiety, especially at higher doses, and in genetically vulnerable people can precipitate or exacerbate psychosis [11] Strong evidence. See THC Dose and Anxiety for dose-dependent effects.
Drug interactions with CBD
CBD inhibits cytochrome P450 enzymes (especially CYP3A4 and CYP2C19) and can raise plasma levels of co-administered drugs; this is relevant for medications including tacrolimus, warfarin, some antiepileptics, and possibly methotrexate and other IBD medications [12] Strong evidence. Talk to your pharmacist if you use CBD alongside immunosuppressants. See CBD and Methotrexate for details on a common combination.
Smoking-related harm
Smoked cannabis irritates airways and can worsen respiratory symptoms in susceptible patients. Vaporization or oral preparations are preferable for chronic medical use [11] Strong evidence.
Cannabinoid hyperemesis syndrome
Paradoxical severe vomiting in heavy chronic users—easily mistaken for a Crohn's flare or disease progression. This is a recognized syndrome with increasing reports in medical literature [13] Strong evidence.
Sources
- Peer-reviewed Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & Therapeutics. 2010;126(1):21–38.
- Peer-reviewed Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129(2):437–453.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276–1280.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn's disease, a randomized controlled trial. Journal of Crohn's and Colitis. 2021;15(11):1799–1806.
- Peer-reviewed Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of Crohn's disease. Cochrane Database of Systematic Reviews. 2018;11:CD012853.
- Peer-reviewed Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2013;19(13):2809–2814.
- Peer-reviewed Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behavioural Pharmacology. 2005;16(5–6):297–313.
- Peer-reviewed Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn's disease, a randomized controlled trial. Digestive Diseases and Sciences. 2017;62(6):1615–1620.
- Peer-reviewed Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflammatory Bowel Diseases. 2014;20(3):472–480.
- Peer-reviewed Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 2020;14(1):4–22.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. Journal of Medical Toxicology. 2017;13(1):71–87.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Chronic Pain — Evidence summary of cannabis for chronic pain: modest benefit for some, real risks, and ho...
- Cannabis and Inflammatory Bowel Disease — Cannabis relieves symptoms in IBD but does not heal the bowel or replace standard therapy.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- CBD and Methotrexate — A real interaction exists, but human evidence for benefit is absent.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...